$69 postpage LB

Gilead’s Remdesivir Approved for Emergency Use by FDA

  • May 04, 2020 02:34 PM AEST
  • Team Kalkine

The Investigational antiviral drug remdesivir by Gilead Sciences Inc (NASDAQ:GILD) was approved by US Food and Drug Administration (FDA) for emergency use in COVID-19 patients and becomes the first drug supported by early clinical information to be made available to combat the novel coronavirus.

This emergency use authorization (EUA) enables broader use of Remdesivir to treat patients who are hospitalized and having severe COVID-19 disease in the US.

Moreover, the Company disclosed that the optimal dose and duration of treatment for remdesivir in COVID-19 patients is still not known. Under this authorization, the ten day duration is recommended for patients who require invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) and the five day dosing regimen is suggested for patients who do not require invasive mechanical ventilation and/or ECMO.

Gold MTF non-AMP


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK